Among the statins, simvastatin and atorvastatin are known to be metabolized by CYP3A; therefore, inhibition of this enzyme may increase their levels in the blood, resulting in an increased risk of rhabdomyolysis. Here, CYP3A4 is linked to rhabdomyolysis.